(Q37197579)

English

A feasibility study of bevacizumab plus dose-dense doxorubicin-cyclophosphamide (AC) followed by nanoparticle albumin-bound paclitaxel in early-stage breast cancer

scientific article published on 24 February 2011

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

A feasibility study of bevacizumab plus dose-dense doxorubicin-cyclophosphamide (AC) followed by nanoparticle albumin-bound paclitaxel in early-stage breast cancer (English)

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

0 references

1 reference

based on heuristic

inferred from title

feasibility study

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Mary Ellen Moynahan

object named as

Mary Ellen Moynahan

26

0 references

object named as

Shanu Modi

22

0 references

object named as

Mark Robson

25

0 references

object named as

Larry Norton

31

0 references

14

object named as

Monica Morrow

1 reference

Europe PubMed Central

18 August 2017

PMC publication ID

2

object named as

Hope Rugo

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

Michelle E Melisko

6

object named as

Michelle Melisko

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

7

object named as

Mark Moasser

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

author name string

Heather L McArthur

1

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

Benjamin Nulsen

3

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

Laura Hawks

4

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

Jill Grothusen

5

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

Matthew Paulson

8

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

Tiffany Traina

9

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

Sujata Patil

10

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

Qin Zhou

11

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

Richard Steingart

12

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

Chau Dang

13

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

Peter Cordeiro

15

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

Monica Fornier

16

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

John Park

17

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

Andrew Seidman

18

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

Diana Lake

19

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

Theresa Gilewski

20

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

Maria Theodoulou

21

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

Gabriella D'Andrea

23

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

Nancy Sklarin

24

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

Steven Sugarman

27

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

Jane E Sealey

28

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

John H Laragh

29

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

Carmen Merali

30

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

Clifford A Hudis

32

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

Maura N Dickler

33

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

language of work or name

0 references

publication date

24 February 2011

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

Clinical Cancer Research

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

17

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

10

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

3398-3407

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

A phase II pilot trial incorporating bevacizumab into dose-dense doxorubicin and cyclophosphamide followed by paclitaxel in patients with lymph node positive breast cancer: a trial coordinated by the Eastern Cooperative Oncology Group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4994894

6 September 2017

Weekly paclitaxel in the adjuvant treatment of breast cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4994894

6 September 2017

Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4994894

6 September 2017

Tumor dormancy and surgery-driven interruption of dormancy in breast cancer: learning from failures

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4994894

6 September 2017

Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4994894

6 September 2017

Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4994894

6 September 2017

Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4994894

6 September 2017

Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4994894

6 September 2017

Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4994894

6 September 2017

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4994894

6 September 2017

Prognostic value of troponin I in cardiac risk stratification of cancer patients undergoing high-dose chemotherapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4994894

6 September 2017

Cardiac-specific troponin I levels to predict the risk of mortality in patients with acute coronary syndromes

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4994894

6 September 2017

A model of human tumor dormancy: an angiogenic switch from the nonangiogenic phenotype

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4994894

14 September 2017

Phase II study of doxorubicin and bevacizumab for patients with metastatic soft-tissue sarcomas.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4994894

14 September 2017

Complications Associated with Mastectomy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4994894

14 September 2017

Immediate breast reconstruction following mastectomy is as safe as mastectomy alone

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4994894

26 June 2018

Hypersensitivity reactions from taxol

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4994894

26 June 2018

RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4994894

3 September 2018

Antiangiogenic and antitumor effects of bevacizumab in patients with inflammatory and locally advanced breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4994894

3 September 2018

Randomized trial comparing cyclophosphamide, epirubicin, and fluorouracil with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer: update of National Cancer Institute of Canada Clinical Trials Gr

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4994894

3 September 2018

Adjuvant docetaxel for node-positive breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4994894

3 September 2018

Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer: results from NSABP B-28.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4994894

3 September 2018

Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4994894

3 September 2018

Serum concentration of cardiac troponin T in patients with cardiomyopathy: a possible mechanism of acute heart failure.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4994894

3 September 2018

Plasma renin activity and plasma prorenin assays.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4994894

3 September 2018

Phase III Trial of Nanoparticle Albumin-Bound Paclitaxel Compared With Polyethylated Castor Oil–Based Paclitaxel in Women With Breast Cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4994894

4 December 2018

Randomized Trial of Dose-Dense Versus Conventionally Scheduled and Sequential Versus Concurrent Combination Chemotherapy as Postoperative Adjuvant Treatment of Node-Positive Primary Breast Cancer: First Report of Intergroup Trial C9741/Cancer and Leu

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4994894

4 December 2018

Sequential or alternating doxorubicin and CMF regimens in breast cancer with more than three positive nodes. Ten-year results

1 reference

https://pubmed.ncbi.nlm.nih.gov/21350003

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Congestive Heart Failure in Older Women Treated With Adjuvant Anthracycline Chemotherapy for Breast Cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/21350003

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Adjuvant dose-dense doxorubicin plus cyclophosphamide followed by dose-dense nab-paclitaxel is safe in women with early-stage breast cancer: a pilot study

1 reference

https://pubmed.ncbi.nlm.nih.gov/21350003

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Laragh's lessons in pathophysiology and clinical pearls for treating hypertension

1 reference

https://pubmed.ncbi.nlm.nih.gov/21350003

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Complications in postmastectomy breast reconstruction: two-year results of the Michigan Breast Reconstruction Outcome Study

1 reference

https://pubmed.ncbi.nlm.nih.gov/21350003

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1158/1078-0432.CCR-10-1969

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q37197579&oldid=2180725373"